Opioid Dependence
Conditions
Brief summary
Many buprenorphine treatment programs do not have services dedicated to adolescents and young adults. As a precursor to developing and evaluating an adolescent and young adult buprenorphine treatment program at APT Foundation Inc, we propose to conduct a 1 year prospective study of 16 to 25 year old treatment-seeking individuals enrolled in the APT Adolescent and Young Adult Suboxone Program
Detailed description
Participants will consent to in-person assessments and monthly chart reviews. We anticipate that the results from this study will inform the development of future services targeted towards adolescents and young adults with opioid dependence.
Interventions
OTHERNaturalistic Prospective Cohort
Follow subjects through 1 year of naturalistic buprenorphine treatment
Sponsors
Yale University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 25 Years
Healthy volunteers
No
Inclusion criteria
* Ages 16 through 25 at time of induction * Meet criteria for enrollment in the APT Adolescent and Young Adult Suboxone Program (Opioid Dependence per DSM-V criteria; no contraindications to buprenorphine (concomitant benzodiazepine, alcohol use, sedative use), * Stable enough to participate in outpatient care/intensive outpatient care for at least 12 weeks; * Can commit to at least 12 weeks of treatment through the APT Adolescent and Young Adult Suboxone Program * Are willing to provide locator information for follow-up. * Are fluent in English and have a 6th grader or higher reading level
Exclusion criteria
* Have an untreated bipolar or schizophrenic disorder, or active suicidal ideation * Are physically dependent on alcohol, benzodiazepines, or other sedatives. * Are in custody of the Department of Children and Families
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Opioid Use Patterns | baseline | To describe the progression of opioid use among adolescents and young adults participating in buprenorphine treatment, the subjects will fill out time line follow back surveys to describe opioid use patterns. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Opioid Use Patterns | One year | Urine drug screen results (opioids (and type if noted) benzodiazepines, marijuana, , cocaine, amphetamines) collected monthly from medical charts. |
| Cigarette Use Patterns | One year | To describe the progression of cigarette use among adolescents and young adults participating in buprenorphine treatment, the subjects will fill out time line follow back surveys to describe cigarette use patterns. |
Countries
United States
Outcome results
None listed